In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Praxis Precision Medicines, with a price target of $270.00. The company’s shares closed yesterday at $53.02.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Rahimi covers the Healthcare sector, focusing on stocks such as Praxis Precision Medicines, Crinetics Pharmaceuticals, and Nektar Therapeutics. According to TipRanks, Rahimi has an average return of 13.1% and a 41.74% success rate on recommended stocks.
In addition to Piper Sandler, Praxis Precision Medicines also received a Buy from Truist Financial’s Joon Lee in a report issued yesterday. However, on September 23, TR | OpenAI – 4o reiterated a Hold rating on Praxis Precision Medicines (NASDAQ: PRAX).
Based on Praxis Precision Medicines’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $71.13 million. In comparison, last year the company earned a revenue of $357 thousand and had a GAAP net loss of $32.68 million
Read More on PRAX:
/Super%20Micro%20Computer%20Inc%20logo%20on%20building-by%20Poetra_RH%20via%20Shutterstock.jpg)
